Selected article for: "global spread and Hubei province"
Author: Kucukoglu, Kaan; Faydalı, Nagihan; Bul, Dilek
Title: What are the drugs having potential against COVID-19?
  • Cord-id: kjnn4sth
  • Document date: 2020_9_10
    • ID: kjnn4sth
    Snippet: A disease emerged in the city of Wuhan, Hubei Province, Central China in the last month of 2019. It was pneumonia caused by a newly emerged coronavirus called COVID-19, later. Coronaviruses are enveloped RNA viruses belong to the Betacoronavirus family and infected birds, humans, and other mammals. In March 2020, the World Health Organization declared the COVID-19 outbreak could be characterized as a global pandemic because the disease spread, and a large number of people were infected and died
    Document: A disease emerged in the city of Wuhan, Hubei Province, Central China in the last month of 2019. It was pneumonia caused by a newly emerged coronavirus called COVID-19, later. Coronaviruses are enveloped RNA viruses belong to the Betacoronavirus family and infected birds, humans, and other mammals. In March 2020, the World Health Organization declared the COVID-19 outbreak could be characterized as a global pandemic because the disease spread, and a large number of people were infected and died in many countries on different continents by virtue of this new virus. Now, intensive work is underway about the pathogenic mechanisms and epidemiological properties of COVID-19, and a great effort is made to develop effective specific therapeutic drugs, vaccines, and/or treatment strategies against these diseases. Herein, we have focused on all treatment options available against COVID-19 pneumonia in this text.

    Search related documents:
    Co phrase search for related documents
    • abl kinase and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • abl kinase inhibitor and action mechanism: 1
    • abl kinase inhibitor and acute respiratory syndrome: 1, 2, 3
    • abl kinase inhibitor imatinib and action mechanism: 1
    • abl kinase inhibitor imatinib and acute respiratory syndrome: 1, 2, 3
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and acute chronic: 1, 2, 3, 4, 5, 6
    • action mechanism and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • action mechanism and acute lung injury ards: 1, 2, 3, 4
    • action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active compound and acute ards respiratory distress syndrome: 1, 2
    • active compound and acute chronic: 1, 2, 3
    • active compound and acute lung injury: 1, 2, 3
    • active compound and acute lung injury ards: 1
    • active compound and acute respiratory distress syndrome: 1, 2
    • active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ards respiratory distress syndrome and adaptive viral infection immune response: 1
    • acute ards respiratory distress syndrome and adaptive viral infection immune response innate: 1